Interactions of Bevacizumab with chitosan biopolymer nanoparticles: Molecular modeling and spectroscopic study

Abdi, Fereshteh; Arkan, Elham; Mansouri, Kamran; Shekarbeygi, Zahra; Barzegari, Ebrahim

doi:10.1016/j.molliq.2021.116655

Cited by 5 publications

(4 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These nanoparticles, loaded with antiangiogenic drugs such as seramin and bevacizumab, demonstrated antiangiogenic effects and reduced levels of inflammation and fibrosis compared to free bevacizumab. Together, these studies showcase the potential of albumin nanoparticles as a topical treatment for corneal neovascularization (CNV) and other posterior eye diseases [ 183 , 184 , 185 ]. The abundance, biocompatibility, and availability of cellulose and its derivatives offer significant advantages for this biomaterial [ 186 ].…”

Section: Biopolymeric Drugs Delivery Systemsmentioning

confidence: 99%

Biopolymeric Innovations in Ophthalmic Surgery: Enhancing Devices and Drug Delivery Systems

Wu,

Khan,

Liao

et al. 2024

Polymers

View full text Add to dashboard Cite

The interface between material science and ophthalmic medicine is witnessing significant advances with the introduction of biopolymers in medical device fabrication. This review discusses the impact of biopolymers on the development of ophthalmic devices, such as intraocular lenses, stents, and various prosthetics. Biopolymers are emerging as superior alternatives due to their biocompatibility, mechanical robustness, and biodegradability, presenting an advance over traditional materials with respect to patient comfort and environmental considerations. We explore the spectrum of biopolymers used in ophthalmic devices and evaluate their physical properties, compatibility with biological tissues, and clinical performances. Specific applications in oculoplastic and orbital surgeries, hydrogel applications in ocular therapeutics, and polymeric drug delivery systems for a range of ophthalmic conditions were reviewed. We also anticipate future directions and identify challenges in the field, advocating for a collaborative approach between material science and ophthalmic practice to foster innovative, patient-focused treatments. This synthesis aims to reinforce the potential of biopolymers to improve ophthalmic device technology and enhance clinical outcomes.

show abstract

Section: Biopolymeric Drugs Delivery Systemsmentioning

confidence: 99%

Biopolymeric Innovations in Ophthalmic Surgery: Enhancing Devices and Drug Delivery Systems

Wu,

Khan,

Liao

et al. 2024

Polymers

View full text Add to dashboard Cite

show abstract

“…Importantly, the liposo-mal constituents are very flexible for chemical modification, which can be tailored to the physiochemical properties of the guest and the biological microenvironment. Altering the head group charge using positively charged stearyl amine or negatively charged diacetyl phosphate has been used in ocular drug delivery to selectively change their interactions with mucin and corneal permeability [55]. An important method to modify the surface of liposomes to make them more stable and better suited for certain applications is the use of polyamidoamine (PAMAM) coats.…”

Section: Liposomesmentioning

confidence: 99%

“…Abdi et al explored the interaction between chitosan nanoparticles and bevacizumab [55]. Study showed that chitosan and bevacizumab had low interactions between one another, thus allowing efficient capture and release of bevacizumab.…”

Section: Polymers Nanoparticles and Microparticles (Mps)mentioning

confidence: 99%

Overcoming Treatment Challenges in Posterior Segment Diseases with Biodegradable Nano-Based Drug Delivery Systems

Joly-Chevrier

Akbar

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Posterior segment eye diseases present a challenge in treatment due to the complex structures in the eye that serve as robust static and dynamic barriers, limiting the penetration, residence time, and bioavailability of topical and intraocular medications. This hinders effective treatment and requires frequent dosing, such as the regular use of eye drops or visits to the ophthalmologist for intravitreal injections, to manage the disease. Moreover, the drugs must be biodegradable to minimize toxicity and adverse reactions, as well as small enough to not affect the visual axis. The development of biodegradable nano-based drug delivery systems (DDSs) can be the solution to these challenges. First, they can stay in ocular tissues for longer periods of time, reducing the frequency of drug administration. Second, they can pass through ocular barriers, offering higher bioavailability to targeted tissues that are otherwise inaccessible. Third, they can be made up of polymers that are biodegradable and nanosized. Hence, therapeutic innovations in biodegradable nanosized DDS have been widely explored for ophthalmic drug delivery applications. In this review, we will present a concise overview of DDSs utilized in the treatment of ocular diseases. We will then examine the current therapeutic challenges faced in the management of posterior segment diseases and explore how various types of biodegradable nanocarriers can enhance our therapeutic arsenal. A literature review of the pre-clinical and clinical studies published between 2017 and 2023 was conducted. Through the advances in biodegradable materials, combined with a better understanding of ocular pharmacology, the nano-based DDSs have rapidly evolved, showing great promise to overcome challenges currently encountered by clinicians.

show abstract

“…Then, 1 ml of TPP solution at 900 rpm/0.2ml per min were added to the chitosan solution containing Bevacizumab. The prepared chitosan nanoparticles were then lyophilized and stored at 4°C [23]. To lipid-coating the chitosan nanoparticles containing Bevacizumab (Lip-Chi-Bev NPs), 16 mg of chitosan nanoparticles containing Bevacizumab (10 mg Bevacizumab) was dispersed in 50 ml of 45°C water.…”

Section: Synthesis Of Lipid-coated Chitosan-bevacizumab Nanoparticles...mentioning

confidence: 99%

The possibility of angiogenesis inhibition in cutaneous melanoma by Bevacizumab-loaded lipid-chitosan nanoparticle

Abdi

Arkan

Eidizadeh

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Cutaneous malignant melanoma is fastest-growing cancer in white populations with a large majority of dermal cancer death. The activity of vascular endothelial growth factors (VEGFs) results in the signaling of a variety of downstream intracellular pathways that ultimately leads to cell activation, proliferation, migration, and angiogenesis. VEGF inhibitors such as Bevacizumab are widely used in chemotherapy with systemic administration, which in many cases is associated with a variety of side effects. Here, we designed and synthesized a lipid-polymer nanoparticle for local administration of Bevacizumab. Drug release, dermal absorption, and the effects of synthesized nanoparticles containing Bevacizumab on cell proliferation and in vitro and in vivo angiogenesis were investigated. Encapsulating Bevacizumab in the synthesized nanoparticles resulted in a significant increase in its dermal absorption compared to free Bevacizumab. Also, the suppressor effects of Bevacizumab encapsulated in the synthesized nanoparticle on cell proliferation and angiogenesis were significantly more than those of free Bevacizumab. Our findings indicate the remarkable effects of lipid-polymer nanoparticles in dermal absorption and in maintaining Bevacizumab bioactivity, suggesting therapeutic benefits of local Bevacizumab administration for angiogenesis-related disorders such as cutaneous melanoma.

show abstract

Interactions of Bevacizumab with chitosan biopolymer nanoparticles: Molecular modeling and spectroscopic study

Cited by 5 publications

References 64 publications

Biopolymeric Innovations in Ophthalmic Surgery: Enhancing Devices and Drug Delivery Systems

Biopolymeric Innovations in Ophthalmic Surgery: Enhancing Devices and Drug Delivery Systems

Overcoming Treatment Challenges in Posterior Segment Diseases with Biodegradable Nano-Based Drug Delivery Systems

The possibility of angiogenesis inhibition in cutaneous melanoma by Bevacizumab-loaded lipid-chitosan nanoparticle

Contact Info

Product

Resources

About